Trial Profile
A study to detect the biomarkers which indicate efficacy of rituximab in patients treated for neuro-immunological diseases.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Sep 2015
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Autoimmune diseases of the nervous system
- Focus Biomarker; Pharmacodynamics
- 09 Sep 2015 New trial record